Issue link: https://www.e-digitaleditions.com/i/1532011
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Inhalation February 2025 31 SPECIAL SECTION Formulation Development/Excipients This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Integrated solutions for pulmonary and nasal delivery With 30+ years' experience in pulmonary and nasal delivery, Catalent offers integrated solutions with clinical- to commercial-scale development and man- ufacturing capabilities for dry powder inhalers and vials for nebulization as well as unit-dose, bi-dose and multi-dose nasal products. In addition, Catalent provides comprehensive analytical, bioanalytical and clinical supply services to support your molecule from development through product launch and beyond. With state-of-the-art facilities in Boston, Massachu- setts and Morrisville, North Carolina, Catalent can handle the most complex projects and help bring your inhaled therapy to market, faster. Catalent Inhalation US: +1 888 SOLUTION (765-8846) solutions@catalent.com www.catalent.com Particle engineering services Particle engineering is being used increasingly in drug development, particularly for complex dosage forms such as OINDPs, where deposition in the smaller air- ways is key to efficacy. Particle engineering can offer many advantages in terms of tailoring the particle size for targeted delivery, as well as offering a more con- trolled manufacturing process, which is also suitable for the formulation of biologics. Intertek is an expert in the spray drying of small and large molecules for respiratory products and has partnerships in place that support other particle engineering approaches, such as anti-solvent precipitation. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com Role of excipients for respiratory delivery Building upon more than 20 years of experience, Lonza continues to drive research in formulation for inhaled delivery of biologics. Excipient choice in drug formulation plays a key role in this process, and when combining a large molecule with one or more excip- ients, factors such as their own properties, route of administration, dosage form and processing condi- tions need to be considered. With dedicated technol- ogies and facilities, Lonza's scientists are identifying new, leading approaches with excipients and provid- ing support for navigating the regulatory landscape. Lonza Small Molecules US: +1 813 286-0404 small.molecules@lonza.com www.lonza.com